IMPL
$0.04
Revenue | $5.02Mn |
Net Profits | $-13.81Mn |
Net Profit Margins | -275.01% |
Impel Pharmaceuticals Inc’s revenue jumped 62.98% since last year same period to $5.02Mn in the Q3 2023. On a quarterly growth basis, Impel Pharmaceuticals Inc has generated -23.71% fall in its revenue since last 3-months.
Impel Pharmaceuticals Inc’s net profit jumped 66.27% since last year same period to $-13.81Mn in the Q3 2023. On a quarterly growth basis, Impel Pharmaceuticals Inc has generated -87.77% fall in its net profits since last 3-months.
Impel Pharmaceuticals Inc’s net profit margin jumped 79.3% since last year same period to -275.01% in the Q3 2023. On a quarterly growth basis, Impel Pharmaceuticals Inc has generated -146.12% fall in its net profit margins since last 3-months.
EPS Estimate Current Quarter | -0.21 |
EPS Estimate Current Year | -0.21 |
Impel Pharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at -0.21 - a 41.67% jump from last quarter’s estimates.
Impel Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at -0.21.
Earning Per Share (EPS) | 0 |
Impel Pharmaceuticals Inc’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q4 2023. This indicates that the Impel Pharmaceuticals Inc has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Earnings Date | Estimated EPS | Reported EPS | Surprise % |
---|---|---|---|
2023-05-12 | -0.9 | -1.27 | -41.11% |
2023-11-14 | -0.36 | -0.58 | -61.11% |
2024-03-22 | -0.21 | 0 | 100% |
2023-08-18 | -0.65 | -0.31 | 52.31% |